Pharmaceutical Boehringer Ingelheim announced today that the US Food and Drug Administration has approved new labeling for Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray that includes data showing a meaningful reduction in chronic obstructive pulmonary disease (COPD) exacerbations driven by tiotropium, which is the active ingredient in Spiriva Respimat (tiotropium bromide) Inhalation Spray. 11 October 2018